Grant Review Philosophy

I should state at the outset that I have no ax to grind. I retired as a professor of physiology a few years ago and no longer apply for research grants. In my time, I have seen the system from both sides, from that of a study section and mostly as a recipient of sensible and, on occasion, senseless evaluations. Reading your report on the National Institutes of Health's new system for evaluating research grants (R. Finn, The Scientist, Aug. 18, 1997, page 1) filled me with apprehension. Investi

Written byPinter
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

I should state at the outset that I have no ax to grind. I retired as a professor of physiology a few years ago and no longer apply for research grants. In my time, I have seen the system from both sides, from that of a study section and mostly as a recipient of sensible and, on occasion, senseless evaluations.

Reading your report on the National Institutes of Health's new system for evaluating research grants (R. Finn, The Scientist, Aug. 18, 1997, page 1) filled me with apprehension. Investigators and study sections evaluating grant applications are both in the business of trying to predict the future. It is not unfair, therefore, to judge NIH's new system by the same criteria by which it proposes to evaluate research grants. Three of these are:

At best, the answer to each of these questions is that nobody knows; therefore, the new system doesn't ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies